Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.61 |
| ▸ | ECE1 | P42892 | 6/20 | 0.60 |
| ▸ | CTSL | P07711 | 1/20 | 0.59 |
| ▸ | MMP2 | P08253 | 4/20 | 0.58 |
| ▸ | MMP8 | P22894 | 4/20 | 0.58 |
| ▸ | MMP9 | P14780 | 3/20 | 0.58 |
| ▸ | MMP1 | P03956 | 2/20 | 0.58 |
| ▸ | TACR3 | P29371 | 1/20 | 0.57 |
| ▸ | GHSR | Q92847 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30051618 | 1.00 | ACE (0.61) | ACEECE1CTSLMMP2MMP8 | |
| SCHEMBL29380319 | 0.94 | ERAP2 (0.64) | ECE1MMP2MMP8MMP9MMP1 | |
| SCHEMBL30278841 | 0.93 | ERAP2 (0.60) | ACEECE1CTSLMMP2MMP8 | |
| SCHEMBL30052548 | 0.92 | CTSC (0.64) | ACEECE1CTSLMMP2MMP8 | |
| SCHEMBL30052868 | 0.90 | KDM4E (0.60) | ACEECE1CTSLMMP2MMP8 | |
| SCHEMBL30051322 | 0.90 | ECE1 (0.64) | ACEECE1MMP2MMP8MMP9 | |
| SCHEMBL30051762 | 0.89 | ACE (0.56) | ACEECE1CTSLMMP2MMP8 | |
| SCHEMBL30974456 | 0.88 | MMP2 (0.57) | ACEECE1CTSLMMP2MMP8 | |
| SCHEMBL29679927 | 0.88 | CTSL (0.55) | ACEECE1CTSLMMP2MMP8 | |
| SCHEMBL24719147 | 0.88 | BCL2A1 (0.64) | ACEECE1CTSLTACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0234186-B1 | USE OF OLIGOPEPTIDS FOR THE TREATMENT OF CEREBRAL DISORDERS | Fresenius AG (DE) | 1991-11-06 | — | — | EP | disclosed |
| US-5036052-A | Containing a dipeptide of tryptophan and alanine or lecine and no stabilizer; discoloration inhibition | MORISHITA PHARMACEUTICAL CO., LTD. (JP) | 1991-07-30 | — | — | US | disclosed |
| EP-0347890-A1 | Amino acid nutrient compositions | Roussel Morishita Co., Ltd. (JP) | 1989-12-27 | — | — | EP | disclosed |
| EP-0234186-A1 | Use of oligopeptids for the treatment of cerebral disorders | Fresenius AG (DE) | 1987-09-02 | — | — | EP | disclosed |